Earnings call transcript: KP Tissue Q4 2024 sees record revenue growth

KP Tissue Inc. reported a record annual revenue of $2 billion for 2024, with Q4 revenue reaching $539.6 million, marking an 11.9% year-over-year increase. Despite these gains, the company posted a net loss of $13.7 million for the quarter, contrasting with a net income of $16.5 million in Q4 2023. The stock price saw a slight increase of 0.5% following the earnings announcement, reflecting cautious investor optimism amid trade uncertainties. According to InvestingPro analysis, the company currently trades at an attractive P/E ratio of 12.5x, with analysts expecting net income growth this year.

Key Takeaways

• Record annual revenue of $2 billion in 2024.
• Q4 2024 revenue grew by 11.9% year-over-year.
• Net loss of $13.7 million in Q4 contrasts with prior year’s profit.
• Stock price increased by 0.5% post-announcement.
• No Q1 2025 profit guidance due to trade uncertainties.

Company Performance

KP Tissue’s performance in 2024 was marked by significant revenue growth, achieving a 9.4% increase year-over-year, driven by strong demand in the tissue category. However, the company faced challenges in profitability, posting a net loss in Q4 2024. This was attributed to increased capital expenditures and ongoing trade uncertainties affecting cost structures.

Financial Highlights

• Revenue: $539.6 million in Q4 2024, up 11.9% YoY.
• Full Year Revenue: $2 billion, up 9.4%.
• Adjusted EBITDA: $66.8 million in Q4 2024, up 9.2% YoY.
• Net Loss: $13.7 million in Q4 2024 compared to a net income of $16.5 million in Q4 2023.

Market Reaction

Following the earnings release, KP Tissue’s stock experienced a modest increase of 0.5%, closing at $8.01. This movement reflects a cautious optimism among investors, who are weighing the company’s strong revenue growth against its net loss and the broader market’s trade uncertainties.

Outlook & Guidance

KP Tissue did not provide a profit guidance for Q1 2025, citing uncertainties in the trade environment. However, the company expects continued sales growth in 2025, supported by potential new manufacturing facilities and strategic investments. InvestingPro data shows the company maintains a strong current ratio of 1.03 and a low beta of 0.32, indicating financial stability and lower volatility compared to the broader market. The stock currently trades near its 52-week low, potentially presenting an opportunity for value investors.

Executive Commentary

CEO Dino Bianco emphasized the strength of the tissue category, stating, "The tissue category is a very healthy category. It’s a product that’s in demand." He also highlighted the company’s vigilance regarding trade dynamics, noting, "We are closely monitoring the evolving North American trade environment to assess its impact on our business."

Risks and Challenges

• Trade Uncertainties: Potential tariffs could impact costs and pricing strategies.
• Supply Chain Disruptions: Trade uncertainties may lead to logistical challenges.
• Market Competition: Increased private label growth could pressure market share.
• Capital Expenditures: High investment levels may affect short-term profitability.

Q&A

During the earnings call, analysts inquired about the company’s strategies to mitigate potential tariff impacts. KP Tissue outlined plans to advance inventory into the U.S., shift production, and explore mergers and acquisitions to strengthen its market position.

By maintaining a focus on strategic growth and navigating trade challenges, KP Tissue aims to build on its robust revenue performance in the coming year.

Full transcript - KP Tissue Inc (KPT) Q4 2024:

Conference Operator: Good morning, and welcome to KP Tissue’s Fourth Quarter twenty twenty four Results Conference Call. Today’s call is being recorded for replay. All participants are currently in listen only mode. I will now turn the call over to Doris Gurebuch, Director of Investor Relations. You may begin your conference.

Doris Gurebuch, Director of Investor Relations, KP Tissue: Thank you, operator. Good morning, everyone, and thank you for joining us to review Kruger Products’ fourth quarter twenty twenty four financial results. With me this morning is Dino Bianco, the CEO of KP Tissue and Kruger Products and Michael Key, the CFO of KP Tissue and Kruger Products. Today’s discussion will include certain forward looking statements. Actual results could differ materially from these forward looking statements due to known and unknown risks and uncertainties.

A list of risk factors can be found in our public filings. In addition, today’s discussion will include certain non GAAP financial measures. The reconciliation of these non GAAP financial measures to the most comparable GAAP measure can be found in our MD and A. The press release reporting our Q4 twenty twenty four results was published this morning and will be available on our website at takytushimi.com. The financial statements and MD and A will also be posted on our website and on SEDAR Plus.

The investor presentation to accompany today’s discussion can be found in the Investor Relations section of our website. I will now turn the call over to our CEO, Dino Bianco. Dino?

Dino Bianco, CEO, KP Tissue and Kruger Products: Thank you, Doris. Good morning, everyone, and thank you for joining us for our fourth quarter and full year earnings call for fiscal twenty twenty four. We are pleased with our financial performance in 2024, highlighted by record revenue of more than $2,000,000,000 and strong adjusted EBITDA in all four quarters. We are particularly proud of our profitability results, which were relatively stable in each quarter despite volatile market and input costs. The fourth quarter culminated with double digit revenue growth year over year and a near double digit improvement in terms of adjusted EBITDA.

Looking ahead, we are closely monitoring the evolving North American trade environment to assess its impact on our business. We have developed various scenarios and contingency plans to understand the potential impact to our company. I do believe that as we enter this period of uncertainty, our business is in a very strong position to manage any potential risk. Now let’s take a look at our quarterly numbers on Slide six. Revenue growth of 11.9% in the fourth quarter of twenty twenty four was mainly driven by higher sales volume in The U.

S, favorable selling prices in Canada and a positive foreign exchange impact. Canadian revenues increased 6% in the fourth quarter, while U. S. Sales grew 19.7% on continued business growth in this market. In terms of profitability, adjusted EBITDA improved 9.2% year over year to $66,800,000 in the fourth quarter, mainly due to higher sales volume, increased selling prices, as well as lower marketing and SG and A expenses.

These factors were partially offset by a number of items, including higher pulp prices. Michael will provide you with the details in his financial review. On Slide seven, we have our full year results where we delivered very strong revenue growth of 9.4% and adjusted EBITDA growth of 11% in fiscal twenty twenty four. We have reported eight consecutive quarters of strong financial results following a challenging 2022. This sustained performance reflects the adaptability and resiliency of our teams in the wake of rising inflationary pressure in recent years and the benefit of the new capacity from our recently added new assets.

On slide eight, pulp average prices in Canadian dollars decreased in the fourth quarter of twenty twenty four from the previous quarter, while year over year average prices for NBSK and BEK were up 32.122.9% respectively versus Q4 twenty twenty three. Although market pulp prices declined sequentially in the fourth quarter, industry analysts anticipate prices will rise again in 2025. We’re also keeping a close eye on the Canadian dollar since a weakened Canadian exchange rate could further increase our input costs in 2025. Let’s move on to our operations on Slide nine. We are pleased to report that our assets performed well across the network in 2024.

At Sherbrooke, the successful startup of our new paper machine and facial tissue line exceeded production targets for the year. At Memphis, the turnaround continued to move in the right direction through increased investments in staffing, training and maintenance spending to achieve improved performance. In summary, we delivered improved results at all our sites with ongoing production increases expected in 2025. Let me give a quick word about our capacity outlook on Slide 10. Following the start up of our tissue plant in Sherbook last year, we are currently evaluating the construction of a new manufacturing facility that will contain state of the art TAD paper machine and converting lines.

The proposed plan supports our continued focus to grow revenue, build our market share and offer high quality tissue products to customers across North America. The current uncertainty in the North American business environment will require us to perform additional scenario planning and due diligence on this project before we make any official announcement. Let’s turn to slide 11. We continued investing and expanding our made in Canada positioning in the fourth quarter amid an uncertain trade environment. Our latest marketing campaign is built on the renewed patronism of consumers seeking to buy products made in Canada.

As a long standing Canadian company, Kruger Products is focused on making and selling high quality branded products from coast to coast for Canadian consumers. We also recently activated our Scotty’s Tournament of the Hearts campaign related to the Canadian Women’s Curling Championship. Congratulations to Team Holman for repeating as Canadian champions at the twenty twenty five Scotty’s Tournament of Hearts that was held in Thunder Bay, Ontario. Early in the fourth quarter, we generated record engagement at the twenty first Cashmere Collection show in Toronto. The fashion show and fundraiser, which was enhanced by nationwide live streaming and first ever live voting, celebrated the strength, courage and hope of breast cancer survivors in Canada.

Sixteen of the country’s top designers took part in creating the 2024 collection, including Shaba Linze, who drew inspiration for her mother from her mother’s journey through cancer to design the winning dress made of cashmere bathroom tissue. Over the last twenty years, the cashmere collection has raised over $5,000,000 in support of breast cancer awareness, prevention and treatment programs for its charitable partners, the Canadian Cancer Society and the Quebec Breast Cancer Foundation. In addition, we continued our distribution drive behind our facial tissue business in the fourth quarter with the launch of new Scotty’s Ultra Soft Pocket Packs and Holiday Cubes. And finally, Kruger Products is recognized for his marketing excellence in 2024 with a number of industry awards such as Strady Magazine’s Brand of the Year, a Bronze FE Award for marketing effectiveness related to Scotty’s as well as multiple national and international awards for our cashmere ultra luxe bathroom guide and our Love is Messy media campaign. Turning to slide 12.

The data presented is taken from Nielsen. It shows branded market share over a fifty two week period ended 12/28/2024. Our decline in bathroom tissue and paper towel share in the fourth quarter of twenty twenty four reflects higher pricing that we took in the Canadian consumer segment, which took effect during the fourth quarter. In the facial tissue category, we continue to make incremental gains of total market share reaching 45% at the end of the year. Looking at the Away From Home segment on slide 13, sales volume slightly decreased year over year and sequentially in Q4 twenty twenty four.

Ongoing strong orders coupled with challenges on our paper supply hampered our order fulfillment. We expect that our new paper machine in Sherbrooke will provide additional internal paper in 2025 for our Away From Home business and reduce our external requirements. It should be noted that we are rebranding our away from home segment to Kruger Pro during Q1 twenty twenty five. We intend to leverage our strong consumer brands like Scotty’s, Cashmere and White Cloud to grow this business. Finally, strong fiscal twenty twenty four full year results for our AFH segment, both in terms of revenue and adjusted EBITDA, will provide a solid foundation for future growth.

I will now turn the call over to Michael.

Michael Key, CFO, KP Tissue and Kruger Products: Thank you, Dino, and good morning, everyone. Please turn to Slide 14 for a summary of our financial performance for the fourth quarter of twenty twenty four. As previously mentioned by Dino, we delivered revenue of $539,600,000 and a strong adjusted EBITDA of $66,800,000 slightly above our expectation. Meanwhile, net loss totaled $13,700,000 in the fourth quarter of twenty twenty four compared to a net income of $16,500,000 in the fourth quarter of twenty twenty three. The year over year decrease can be attributed to a higher foreign exchange loss of $33,200,000 greater depreciation expense of $3,300,000 dollars as well as higher interest expense and other finance costs of $2,900,000 These factors were partially offset by a higher adjusted EBITDA of $5,600,000 increased income from non controlling interest of $3,100,000 dollars reduced income tax expense of $2,200,000 and a lower loss on the sale of fixed asset of $1,500,000 In the quarterly segmented view on Slide 15, revenue from our consumer business grew 12.9% year over year to $452,700,000 in the fourth quarter of twenty twenty four.

The double digit increase was due to higher sales volume primarily in The U. S, the positive impact of consumer selling prices in Canada and a more favorable foreign exchange impact on U. S. Dollar sales in the quarter. In the Away From Home segment, the revenue improved 6.8% year over year to $86,900,000 on the strength of higher selling prices.

AFH revenue increased in both U. S. And Canada on a year over year basis. When looking at our consumer adjusted EBITDA in the fourth quarter, it totaled $64,000,000 compared to $59,800,000 in Q4 twenty twenty three with a margin of 14.1% versus 14.9% for the same period last year. On a sequential basis, the consumer adjusted EBITDA grew $1,600,000 from Q3 twenty twenty four.

For our away from home business, adjusted EBITDA amounted to $4,600,000 in the fourth quarter compared to $5,700,000 in Q4 twenty twenty three, a decrease of $1,100,000 with a margin of 5.3 for the quarter. While sequentially AFH adjusted EBITDA declined $2,000,000 from Q3 twenty twenty four. Now moving on to Slide 16, we can review consolidated revenue for Q4 twenty twenty four, which grew $57,300,000 or 11.9% year over year. The increase was driven by higher sales volume primarily in The U. S, favorable selling prices in Canada and a positive FX impact on U.

S. Dollar sales. On a geographic basis, revenue in Canada rose $16,500,000 or 6% year over year, while U. S. Revenues grew $40,800,000 or 19.7%.

On Slide 17, we provide details about year over year profitability in the fourth quarter. The adjusted EBITDA increased by $5,600,000 to $66,800,000 in the quarter, resulting in a margin of 12.4% compared to 12.7% for the same period last year. Several factors account for the year over year growth in adjusted EBITDA. That was the higher sales volume, the increase in selling prices and lower marketing and SG and A expenses. These items were partially offset by a higher pulp price, additional outsourcing activity during the quarter and a greater freight and warehousing costs.

Now if we turn to Slide 18, where we compare Q4 revenue to Q3 twenty twenty four, revenue increased $18,500,000 sequentially or 3.6%, mainly due to the increased selling prices, higher consumer sales volume and a positive FX impact. Geographically, revenue in Canada rose by $9,200,000 or 3.2%, while revenue in The U. S. Grew $9,300,000 or 3.9 percent. On Slide 19, adjusted EBITDA in the fourth quarter improved sequentially by $1,100,000 to $66,800,000 mainly due to the favorable selling prices, lower SG and A expenses and improved sales mix.

These factors were partially offset by higher manufacturing overhead costs as well as greater freight and warehousing expenses. Now turning to our balance sheet and financial position on Slide 20. Our cash position reached $119,500,000 at the end of the fourth quarter, an increase of $8,300,000 from Q3 twenty twenty four. And our net debt at quarter end stood at $1,100,000,000 up $59,000,000 sequentially. Accordingly, our net debt to last twelve month adjusted EBITDA ratio rose to slightly to 4.2 times in the fourth quarter.

In terms of total liquidity, we had $344,600,000 available at the end of the fourth quarter and in addition $16,600,000 of cash was held for the Sherbrooke expansion project. I will conclude my section by reviewing capital expenditures on Slide 21. CapEx for Q4 twenty twenty four was $48,100,000 which included $16,100,000 for the Sherbrooke expansion project. The total CapEx for the fiscal year of 2024 reached $185,500,000 Finally, our CapEx outlook remains between $40,000,000 and $60,000,000 for 2025. This outlook is for our base CapEx and excludes approximately $30,000,000 to $40,000,000 left for the completion of the Sherbrooke expansion project.

Thank you for joining us this morning. And I’ll now turn the call back to Dino. Thank you, Michael.

Dino Bianco, CEO, KP Tissue and Kruger Products: Please turn to slide 23 for my closing comments. Building on fiscal twenty twenty four, we expect strong continued sales growth in 2025. We are closely monitoring the evolving North American trade environment to assess its impact on our business. We believe that the category and our company is in a strong position to manage any potential impacts. We will continue to pass on any necessary market cost increases while delivering against cost and productivity initiatives to protect our margins.

We will continue investing in our brands to drive long term share gains. We expect our new paper machine in Sherbook will enable the reduction of purchased paper in 2025. Our away from home business, which continues to deliver against the sustainable profit model, is being rebranded CougarPRO in Q1 twenty twenty five. And finally, we are developing our organizational capability to strengthen the adaptability and resiliency of our employees in the face of an uncertain environment. As we enter a period of great business uncertainty, we believe the foundation of our business is in a strong position.

However, given the evolving news and volatility, we will not provide profit guidance for Q1 twenty twenty five. Our intention is that once there is more market clarity, we will return to providing quarterly guidance. We will now be happy to take your questions.

Conference Operator: Thank you. Your first question comes from the line of Sean Steuart with TD Cowen. Please go ahead.

Sean Steuart, Analyst, TD Cowen: Thank you. Good morning, everyone. A couple of questions. Dino, first, I’d like to start with tariff exposure. You referenced, I guess, some potential to mitigate this exposure.

Wondering if you can give us context there? And can you tell us in 2024 whether specific number general range? How much of your 2024 sales last year were from Canada to The U. S?

Dino Bianco, CEO, KP Tissue and Kruger Products: Yes. Good morning, Sean. It didn’t take long for that question to come up. Obviously, it’s a very important, but an evolving uncertain topic as we continue to watch how it’s unfolding. A couple of things.

First of all, let me talk about the exposure piece because then that will lead to mitigating actions. On the exposure piece, we are about one third of our revenue is what I would call exposed to tariffs. So it’s a range, let’s say, $600,000,000 to $700,000,000 these are all Canadian dollars 6 hundred million dollars to $700,000,000 that would be exposed to a tariff risk on finished goods going primarily from Canada into United States. We would also have some exposures most companies would from the tariff impact on pulp and BSK primarily. Most North American companies source their softwood from Canada.

So there’s a general cost increase for all tissue manufacturers regardless of where they are, particularly as I said United States since it’s a tariff going into The U. S. Our mitigation plan has a few things to play. Certainly, we are and have been moving as much volume in advance into The United States, into our customers, into our warehouses. We are moving as much production as we can with our network into The United States from a short term point of view.

Our expectation is also given the tariff that we would pass that through as a surcharge to our customers. Obviously, it’s a significant amount and we believe as most of any industry will do, we’ll pass it through as a surcharge to our customers. Mid term, we’re looking at we’ve been looking at this for a while. So this isn’t new to tariffs. But mid term, we’re looking at adding additional assets, near in assets, if you will, into The United States.

We’re also continuing to look at M and A activity. And then longer term, as I mentioned in my notes, we’re looking at a new greenfield site or new site. So that would be some of the longer term mid- and longer term actions that we would look at to mitigate the tariff risk.

Sean Steuart, Analyst, TD Cowen: Thanks for all that detail. And with respect to the potential new TAD machine, any and I appreciate you probably want to see how the dust settles here in the trade issue, but any context on scale of that project? And what the cost might look like relative to previous expansion initiatives into that technology?

Dino Bianco, CEO, KP Tissue and Kruger Products: Yes. We announced in our assessment that we were evaluating this project. We had said that to start the project would be one paper machine and converting lines. So it’s basically be a replication of what we started up in Sherbrooke. And I think you’ve seen others who have recently announced new similar machines in The United States.

And you’re seeing costs range from $600,000,000 plus. So I think we’re going to be once we finalize all the costs, it will be likely in similar range to what you’re seeing announced already.

Sean Steuart, Analyst, TD Cowen: And does the timing get pushed out until there’s clarity on what’s going on with trade? Or do you just say, all right, it’s going to be a U. S. Project and what’s more?

Dino Bianco, CEO, KP Tissue and Kruger Products: Yes. I mean, look, we’re looking at it very aggressively. We’re getting to the point now we’re putting the dots on the i’s and the crosses on the t. The cost to do business is a big factor. So the tariffs play into that, but there’s other costs like energy, access to water, access to labor, freight distribution.

So we’re putting it into the model. My point in that comment is that we had said we would announce in early twenty twenty five given what’s happening in the economic environment. It’s not just the tariffs, it’s the exchange rate, it’s the reciprocal tariffs, it’s is there a recession, It’s the global impacts, collateral impacts around freight. So more than just the tariffs, although a lot of it is obviously the tariffs. So we’re going to wait till that all settles out before we make a major announcement like that.

I’m not expecting years of delay. It might be months just to wait to see how this thing shakes out, because we are anxious to get going. And we know the market needs more capacity, particularly in the Ultra Premium. And we are continuing to grow and we’ve shown that with the assets we put in place and we will need new assets. So hopefully, it’s a short period of time if any delay before we announce.

Sean Steuart, Analyst, TD Cowen: Okay. Thanks for that, Dino. I’ll leave it there for now.

Dino Bianco, CEO, KP Tissue and Kruger Products: Thanks, Sean.

Conference Operator: And your next question comes from the line of Hamir Patel with CIBC Capital Markets. Please go ahead.

Hamir Patel, Analyst, CIBC Capital Markets: Hi, good morning. Dino, how is the push to sort of Buy Canada affected your market share stats here in 2025?

Dino Bianco, CEO, KP Tissue and Kruger Products: Yes. Thank you, Amir. Great question. First of all, we our brand identity has always been made in Canada. We’ve been doing made in Canada before it got fashionable to do made in Canada last few months.

We’re reinforcing that point that we are made in Canada. Obviously, it’s a we’re a Canadian company, Canadian production made by Canadians for Canadians. Our brands have been longstanding connections with consumers across this country and Canada. So what we ended up doing is like most companies now that you’re seeing is just picking up on that communication as part of the period that we’re going through now with the Made in Canada mindset both at the retailer level, you’re seeing that and then at the consumer level. So we are very active in activating and activating our both our in store and our marketing programs to support that and our PR quite frankly.

So there’s a lot of press about it. It’s too early to tell. Have we seen it in share yet? You’ll probably start to see it as we get out of the Q1 share period to see that. But we do believe based on activation, we do believe based on the promotions that we are getting additional support on promotions that it should manifest itself and improve share performance.

And

Hamir Patel, Analyst, CIBC Capital Markets: then just given the economic uncertainty, have you seen any signs of the Canadian consumer maybe trading down to some of the lower tier products?

Dino Bianco, CEO, KP Tissue and Kruger Products: Not yet. I mean obviously the growth of private label has been very strong and continues to be strong and really started ramping up during 2022 with the increased inflation that we saw. We saw a bit of it in Q4 from we took pricing in Q4. Whenever we take pricing, we’re always the first to go. There’s always a lag.

There’s always uncertainty in the market. So we end up losing a little bit in the as we’re moving to protect our margin, we lose a little bit on the volume noise for a short period of time. So we saw a little bit of that. I would say I don’t see that as a trend yet. Maybe we will as we go through this.

It’s just part of its normal growth that many of the private label brands have been gaining is continuing, but I haven’t seen any acceleration in that.

Hamir Patel, Analyst, CIBC Capital Markets: Great. Thanks. And then just last question. If you do go forward with a TAD3 project, how do you think about the sort of percent mix debt equity to finance that project?

Dino Bianco, CEO, KP Tissue and Kruger Products: Yes. Probably very similar to what you saw in Sherbrooke, which I think was a sixty four forty debt 40 equity, 60 debt kind of range is the model we like to work within. It could obviously move on the edges just depending on what’s available and where, but that’s kind of the model that we have been adhering to.

Hamir Patel, Analyst, CIBC Capital Markets: Okay. Fair enough. Thanks. That’s all I had. I’ll turn it over.

Dino Bianco, CEO, KP Tissue and Kruger Products: Thanks,

Conference Operator: Your next question comes from the line of Zack Evershed with National Bank Financial. Please go ahead.

Zack Evershed, Analyst, National Bank Financial: Good morning, everyone. This is Nate calling in for Zach. So my next question is, what will be what’s your view on how global pulp markets react to tariffs and the trade war and reciprocal tariffs? And what would KVT’s sourcing playbook be in this scenario? What kind of options are you exploring?

Dino Bianco, CEO, KP Tissue and Kruger Products: Well, I think you raised a question that most people are focused on the tariff and the 25% and what that’s doing. But you raise a great point. There’s a lot of collateral impacts that happen longer term. Short term, it’s hard to do to move supply networks. But in midterm, there’s a lot of collateral impacts.

We’re even looking at what happens to the freight market, very important cost for us as low product flows change etcetera. On the pulp side, obviously, like many tissue companies, we source our hardwood mainly from South America and our softwood mainly from Canada. There are options in Nordic countries. There are obviously U. S.

Softwood and U. S. Hardwood. So we look at the full mix. It’s very important for us that we maintain our quality.

And that narrows down the scope of where you can go. So quality is a very important aspect for us both in our own brands and the in any private label that we produce. So within that constraint, we try to maximize our relationships with our long standing pulp suppliers. And we’ll also look at alternative sources as a backup plan. And you can only do so much of that, but we are looking at that as well.

Zack Evershed, Analyst, National Bank Financial: Thank you. And yes, of course, we can all appreciate the complexity of how the situation is continuously evolving. Thus far, what can you say has been the most disrupted part of the business? And perhaps where do you see the most opportunity amidst all the volatility?

Dino Bianco, CEO, KP Tissue and Kruger Products: Well, one thing I would say and I alluded a little bit to it in my remarks. The tissue category is a very healthy category. It’s a product that’s in demand. We know that demand will be we can predict demand. It’s not a discretionary product.

There’ll be movement within there between quality tiers and so forth. But at the end of the day, I don’t think people are going to stop using tissue because of tariffs or disruption. So I think we’re very pleased that we’re working in a strong category that will continue to grow. I also believe at this point in the cycle that capacity is very tight in the North American market, both in The U. S.

And in Canada and as a North American market, if you will. So capacity is fairly tight. And I think that just my worry is that you could easily get supply disruptions if there’s impacts to the supply chain, because there isn’t a lot of headroom in the supply chain. And it’s instantaneous because inventory levels are fairly low. So we’re just watching to make sure we’re not having supply chain impacts from the tariffs or the availability of freight carriers, etcetera.

So that’s something that we continue to watch. We do not want to get into what we got into during COVID with respect to empty shelves and panic buying. We understand the dramatic impact that has on consumers and retailers. So we’re trying to build some redundancy into our systems as best we can to deal with any supply shocks that may happen because of the tariffs. So that’s the piece that we watch the most and probably most challenging, but also I think the greatest opportunity for us too is to manage through that.

Zack Evershed, Analyst, National Bank Financial: Great color. And with the expectation of the surcharge of the tariffs being passed through, can you give any color as to how quickly retail prices can be adjusted in The

Dino Bianco, CEO, KP Tissue and Kruger Products: U. S? I think we’re talking about inventory levels of two weeks to maybe four weeks. So every retailer is in a different position. And by the way, if you’re a retailer, you’re not just worried about tissue, you get thousands and thousands and thousands of SKUs that are coming from all over the world, quite frankly.

So there’s a lot of work being done in the retailers. You heard some of them speak yesterday, some large retailers about how they’re going to have to respond. We’ve been in close contact with all our retailers, our customers, if you will, in The U. S. And in Canada.

So we’re very close to them and knowing how this is playing out and what the impact is for them and what actions we’re taking. So I suspect in general that on the consumer side of these tariffs anything that you’re buying through a grocery store or grocery channel is going to start hitting the consumer within weeks. Think of vegetables, other staples, etcetera, fruits and so forth. So I think it’s weeks before it starts hitting the consumer, maybe even faster.

Zack Evershed, Analyst, National Bank Financial: Great color. Thank you. And just one last one regarding the new machines ramp up and how that will feed into the AFH segment. How much incremental benefits are you expecting from the reduction in externally sourced paper?

Dino Bianco, CEO, KP Tissue and Kruger Products: We expect as a network that we will be essentially in balance. There’s some grades that we just can’t produce that we’ll have to buy, but that’s a really small portion. For the bulk of our main grades, we will be in balance internally with respect to paper and that will benefit our Cougar Pro division the most because they were as we were short on paper, they were the ones that had to go out and buy paper. So this will I think we’ll start seeing it as we move through 2025 across the business. You’ll start to see that in the Kruger Pro division.

But it isn’t just there’s consistency of paper, the quality of paper and obviously the cost benefit. All those things will materialize in our businesses as we ramp up that machine.

Zack Evershed, Analyst, National Bank Financial: Thank you very much. I’ll turn it over.

Conference Operator: And I’m showing no further questions at this time. I would like to turn it back to Dino Bianco for closing remarks.

Dino Bianco, CEO, KP Tissue and Kruger Products: Thank you. Before I end the call, I want to take the opportunity to thank our 3,000 employees across North America for their continued dedication and efforts to deliver these results, while creating a strong culture and really setting our business up for future success. I am grateful and humbled by this incredible team. And I want to thank you for the work that you’ve done and thank you for the work that you do and will continue to do to continue to look after our consumers and our customers. I also want to thank you all for joining us on the call today.

We look forward to speaking with you again following the release of our first quarter results for 2025. Thank you and have an amazing day.

Conference Operator: Thank you. And ladies and gentlemen, this concludes today’s conference call. Thank you all for participating. You may now disconnect.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.